Relation of multiple inflammatory biomarkers to incident atrial fibrillation

Am J Cardiol. 2009 Jul 1;104(1):92-6. doi: 10.1016/j.amjcard.2009.02.053. Epub 2009 May 4.

Abstract

Basic and clinical studies have suggested that inflammation predisposes to atrial fibrillation (AF). We assessed the association of 12 circulating inflammatory biomarkers (i.e., C-reactive protein, fibrinogen, interleukin-6, intercellular adhesion molecule-1, lipoprotein-associated phospholipase A2 [mass and activity], monocyte chemoattractant protein-1, myeloperoxidase, CD40 ligand, osteoprotegerin, P-selectin, and tumor necrosis factor receptor II) with incident AF in 2863 Framingham Offspring Study participants (mean age 60.7 years, SD = 9.4, 55% women). During follow-up (median 6 years), 148 participants (43% women) developed incident AF. In the multivariable proportional hazards models, the inflammatory biomarker panel was associated with incident AF (p = 0.03). With stepwise selection (p <0.01 for entry and retention), log-transformed osteoprotegerin was associated with incident AF (hazard ratio per SD 1.30, 95% confidence interval 1.08 to 1.56, p = 0.006). Adjusting for interim myocardial infarction or heart failure attenuated the association between osteoprotegerin and incident AF (hazard ratio 1.18, 95% confidence interval 0.98 to 1.43, p = 0.09). In conclusion, circulating osteoprotegerin concentration was significantly associated with incident AF in our community-based sample, possibly mediated by interim cardiovascular events.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Atrial Fibrillation / epidemiology*
  • Atrial Fibrillation / etiology
  • Atrial Fibrillation / microbiology
  • Biomarkers
  • C-Reactive Protein
  • Confidence Intervals
  • Female
  • Germany / epidemiology
  • Humans
  • Incidence
  • Inflammation / complications
  • Inflammation / diagnosis*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Odds Ratio
  • Osteoprotegerin / blood
  • Prospective Studies
  • Risk Factors
  • Survival Analysis

Substances

  • Biomarkers
  • Osteoprotegerin
  • C-Reactive Protein

Grant support